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(CMA) based on Time-and-Motion (TM) simulations designed to
allow comparison of the complexity related to hGH preparation
and administration. METHODS: Nurses naïve to hGH adminis-
tration or similar drug-device combinations were recruited to
evaluate four hGH pen devices via TM simulations. Five video-
taped and timed trials for each product were evaluated based on
four phases: 1) Learning (initial instructions for use); 2) Prepara-
tion (arranging device for use); 3) Administration (actual injec-
tion); and 4) Storage (provide for product viability between
doses). The CMA applied costs related to parental opportunity
costs categorized as wages (U.S. Bureau of Labor Statistics aver-
ages), drugs (First Databank WAC prices), and injection supplies.
RESULTS: Two pen devices (Norditropin NordiFlex NNF, Nor-
ditropin NordiPen NNP) take less Total Time (<) to use than the
comparators (Genotropin GTP < Humatrope PenHTP, p < 0.05).
Most time savings were directly related to differences in Learning
(p < 0.05) and Preparation times (p < 0.05). Between the four
hGH devices, the NNF/NNP pens appeared easier to learn to use
than the HTP/GTP pen devices (NNF = NNP < HTP < GTP,
p < 0.05) and were also easier to prepare for use (GTP < HTP,
p < 0.05). User “learning curve” slopes decreased with practice
(p < 0.05) over the ﬁve trials. Once any product was prepared for
use, Administration and Storage times were nearly identical
(p > 0.05). Parental time cost (opportunity cost) savings were
greater in devices that were easier to Learn and Prepare for use
(NNF 16% < NNP 24% < GTP 7% < HTP). Supplies costs were
<1% of drug costs for all devices. CONCLUSIONS: Simulation-
generated data demonstrated the value of multi-dimensional
product-device analysis and revealed thatNNF andNNP took less
Total Time vs. comparators.
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OBJECTIVE: To assess differences in overall and diabetes-related
cost and utilization between diabetes patients treated with insulin
detemir and insulin glargine. METHODS: Retrospective data
analysis included commercial enrollees in a large US health plan
with medical and pharmacy beneﬁts. Patients were identiﬁed if
their ﬁrst prescription claim (index) for insulin detemir or insulin
glargine occurred between May 1, 2006 and December 31, 2006.
Eligible patients were required to have 6 months of continuous
enrollment pre- and post-index date, no evidence of insulin
detemir or insulin glargine use during pre-index and an A1C
reading during the pre-index period. Primary outcomes include
daily average consumption (DACON) of insulin detemir or
insulin glargine and overall and diabetes-related cost. Differences
in outcomes between insulin detemir and insulin glargine users
were adjusted for baseline characteristics through generalized
linear modeling (GLM). Propensity score matching was used to
reduce selection bias between the two groups. RESULTS: There
were 153 insulin detemir and 640 insulin glargine patients in the
study, with no signiﬁcant difference in age, gender and diabetes
types between the two groups. Adjusted DACON for insulin
detemir users was 34.3 units/day compared to 32.9 units/day for
insulin glargine (p = 0.51). Adjusted diabetes-related pharmacy
cost for insulin detemir users was higher than insulin glargine
patients ($1467 vs. $1255; p < 0.01). However, adjusted
diabetes-related medical cost for insulin glargine users was more
than twice that of insulin detemir users ($2304 vs. $1091;
p < 0.01). Moreover, adjusted overall medical cost for insulin
glargine users was also much higher compared to insulin detemir
patients ($7497 vs. $6221; p < 0.05). No difference in overall
pharmacy cost was observed. CONCLUSION: No signiﬁcant
difference in DACON between insulin detemir and insulin
glargine users was observed. Although insulin detemir patients
pay more for diabetes-related prescription medications, these
costs were more than offset by signiﬁcantly lower diabetes-
related and overall medical costs.
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OBJECTIVE: To examine medical conditions associated with
diabetic neuropathy (DN) and to identify drivers of health care
charges and utilization using administrative claims database.
METHODS: We studied commercially-insured individuals aged
18–64 with 24 months continuous enrollment in a national
health plan. DN patients were identiﬁed by having1 claim with
a DN diagnosis between July 2004 and June 2005. Using pro-
pensity scoring, we selected a demographically-matched control
cohort of patients with diabetes (10:1 ratio to DN). We com-
pared disease prevalence, Year 2 distribution of charges, and
reasons for ER visits and inpatient admissions between DN
patients and controls. Logistic regression was used to assess the
marginal contribution of DN to the most common reasons for
ER and inpatient admissions controlling for differences in overall
illness burden. RESULTS: Compared with controls (n = 86,550),
DN patients (n = 8655) had more unique number of co-morbid
medical conditions (9.7 vs. 6.8) and higher ($41,394 vs.
$16,983) total medical charges. Both groups had the highest
medical charges for inpatient services, followed by outpatient
hospital and pharmacy use. Compared with controls, more DN
patients had ER visits (13% vs. 9%), inpatient hospital encoun-
ters (28% vs. 13%), and longer hospitalizations (2.4 vs. 0.6
days). The top ﬁve reasons for ER visits were the same for both
groups, with nonspeciﬁc backache being the most common.
Three of the top ﬁve reasons for inpatient admissions were also
the same: coronary atherosclerosis and other chronic ischemic
heart disease, chest pain, and cellulitis. Controlling for excess
illness burden, DN patients were still at a higher risk for hospi-
talizations due to chest pain, heart failure, and cellulitis.
CONCLUSION: DN patients had signiﬁcantly more co-morbid
medical conditions, ER visits, inpatient admissions, and longer
hospitalizations than age-and-sex matched controls.
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OBJECTIVE:To examine health care expenditures and utilization
among gout patients by severity of renal disease. METHODS: A
retrospective claims analysis using commercial enrollees in a U.S.
health plan age 18, treated with pharmaceuticals for incident
gout between Janaury 1, 2002 and December 31, 2005, without
cancer. Annual health service costs and utilization were compared
by severity of renal disease (using a claims-based algorithm) with
descriptive analysis and generalized linear modeling (GLM).
RESULTS: Renal disease was evident in 745 (9%) of 8039 sub-
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